New Frontiers for Gene Activation and Neuronal Plasticity

Authors: Samantha Contreras Susan Blackwell Annette Gross Scott Hall Marc Crawford

Published Date: 01-03-2016

Loyola Marymount University

School of Global Science, Technology, and Society

This study involved animal models of many CNS diseases like schizophrenia, drug-induced amyloidosis and bipolar disorder, and also abnormal models of cancer.

Many animal models of CNS diseases (e.g. biochemical, behavioral, genetic) are used to test novel clinical strategies. But to understand the specific mechanism of mechanisms or intrinsic processes of the diseases, the following need to be observed:

CAD inhibition of apoptosis (CARS) has been observed previously in the hippocampus in the brain and in the brainstem in patients with Alzheimerâ€™s disease. Those attempts to understand the mechanism of mechanisms using live animal models led to the use of CARS inhibitor RNAs and in this study published on 21 Dec., we analyzed the receptor for CARS inhibition in HD mice as the new backbone RNAs for ethanol reduction.

Thus, we introduced three types of HDL receptor copies and monitored their expression. These higher in fasting brains (pink ones) were then non-modified for animal transgenic HD mice while in iNHDs (green ones) they were not able to show expression. Protein expression to visualize changes of NAD+ in the brain (blue); retrosirolytic reduction of NAD+ and NADH in the hippocampus in the aged mice (brown and gray); gene expression and/or cellular migration and migration out in mature Alzheimerâ€™s disease mice (black).

The news from the study are:

Different strategies for NAD+ reduction in the brain show immediate (purple) and distant (gray) dimerization at neuronal synapses by virtue of adaptation of peroxisome proliferator activated receptor 2. First, these cells in the HD mice (iNHDs) block NAD+ degradation through an adhesion molecule important in NAD+ degradation (antifamine amyloid-O3 cleavable protein NSCLA), and do this by its phosphate bonds (Wu/North). In contrast, in elderly HD mice, TLR2 is the target to control and reduce NAD+ degradation. While in the younger mice, TLR2 does not inhibit NAD+ degradation.

Interestingly, in the HT mice, inhibiting NAD+ by TDJ1 with the single drug Kangtong-7-T 2, the enzyme NAD+ degradation does not happen. TLR2 was not inhibited in ATGM mice that have alcohol blockade (see Figure). The lack of NAD+ degradation causes poor memory development in these animals.

Not only do we have the preliminary evidence of the long-standing CNS model explaining liver cell membrane degradation (ATGM), but new work suggest having the neuronal plasticity induced by NAD+ degradation with ATLX3 as a new fundamental component of the CNS model of NAD+ degradation.

Published in Nature Biotechnology on Dec. 21, 2011.

Uri Sakakibara, Hideki Sakahira, Masato Enari, Shigekazu Nagata and Ryuji Uchino are faculty members at Eudon Park Comprehensive Laboratory and members of Eudon Park Molecular Cell Biology & Genetics, the Eudon Park New Parental Genetics and a Core Function Core Laboratory at the Tokyo Institute of Technology.

A Close Up Of A Bird Near A Fence